HLA-C and neoplasm: After harvesting, either from the patient’s tumor or from blood, the immune effector cells are selected and their functionality may be improved in vitro—e.g., through genetic modification to express a chimeric antigen receptor (CAR) that targets a specific protein or a TCR to specifically recognize a peptide/MHC complex—followed by re-administration back into the patient.